Tags

Type your tag names separated by a space and hit enter

A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk.
Breast Cancer Res Treat. 2008 Jan; 107(2):289-301.BC

Abstract

PURPOSE

To measure the effectiveness of a tailored decision aid (DA) designed to help women make informed decisions about genetic testing for breast/ovarian cancer risk.

METHODS

A total of 145 women were randomized to receive the DA or a control pamphlet at the end of their first genetic counseling consultation. Of these, 120 (82.8%) completed two questionnaires, 1 week and 6 months post-consultation.

RESULTS

While the DA had no effect on informed choice, post-decisional regret or actual genetic testing decision, the trial showed that women who received the DA had higher knowledge levels and felt more informed about genetic testing than women who received the control pamphlet (chi(2)(2) = 6.82; P = 0.033; chi(2)(1) = 4.86; P = 0.028 respectively). The DA also helped women who did not have blood drawn at their first consultation to clarify their values with regards to genetic testing (chi(2)(1) = 5.27; P = 0.022). Women who received the DA were less likely to share the information with other family members than women in the control condition (chi(2)(1) = 8.78; P = 0.003).

CONCLUSIONS

Decision aids are an effective decision-support strategy for women considering genetic testing for breast/ovarian cancer risk, and are most effective before the patient has made a decision, which is generally at the point of having blood drawn.

Authors+Show Affiliations

Department of Psychology, Macquarie University, Sydney, NSW, Australia. c.wakefield@unsw.edu.auNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17333332

Citation

Wakefield, Claire E., et al. "A Randomized Controlled Trial of a Decision Aid for Women Considering Genetic Testing for Breast and Ovarian Cancer Risk." Breast Cancer Research and Treatment, vol. 107, no. 2, 2008, pp. 289-301.
Wakefield CE, Meiser B, Homewood J, et al. A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk. Breast Cancer Res Treat. 2008;107(2):289-301.
Wakefield, C. E., Meiser, B., Homewood, J., Peate, M., Taylor, A., Lobb, E., Kirk, J., Young, M. A., Williams, R., Dudding, T., & Tucker, K. (2008). A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk. Breast Cancer Research and Treatment, 107(2), 289-301.
Wakefield CE, et al. A Randomized Controlled Trial of a Decision Aid for Women Considering Genetic Testing for Breast and Ovarian Cancer Risk. Breast Cancer Res Treat. 2008;107(2):289-301. PubMed PMID: 17333332.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk. AU - Wakefield,Claire E, AU - Meiser,Bettina, AU - Homewood,Judi, AU - Peate,Michelle, AU - Taylor,Alan, AU - Lobb,Elizabeth, AU - Kirk,Judy, AU - Young,Mary-Anne, AU - Williams,Rachel, AU - Dudding,Tracy, AU - Tucker,Kathy, AU - ,, Y1 - 2007/02/27/ PY - 2007/01/21/received PY - 2007/01/30/accepted PY - 2007/3/3/pubmed PY - 2009/2/5/medline PY - 2007/3/3/entrez SP - 289 EP - 301 JF - Breast cancer research and treatment JO - Breast Cancer Res. Treat. VL - 107 IS - 2 N2 - PURPOSE: To measure the effectiveness of a tailored decision aid (DA) designed to help women make informed decisions about genetic testing for breast/ovarian cancer risk. METHODS: A total of 145 women were randomized to receive the DA or a control pamphlet at the end of their first genetic counseling consultation. Of these, 120 (82.8%) completed two questionnaires, 1 week and 6 months post-consultation. RESULTS: While the DA had no effect on informed choice, post-decisional regret or actual genetic testing decision, the trial showed that women who received the DA had higher knowledge levels and felt more informed about genetic testing than women who received the control pamphlet (chi(2)(2) = 6.82; P = 0.033; chi(2)(1) = 4.86; P = 0.028 respectively). The DA also helped women who did not have blood drawn at their first consultation to clarify their values with regards to genetic testing (chi(2)(1) = 5.27; P = 0.022). Women who received the DA were less likely to share the information with other family members than women in the control condition (chi(2)(1) = 8.78; P = 0.003). CONCLUSIONS: Decision aids are an effective decision-support strategy for women considering genetic testing for breast/ovarian cancer risk, and are most effective before the patient has made a decision, which is generally at the point of having blood drawn. SN - 1573-7217 UR - https://www.unboundmedicine.com/medline/citation/17333332/A_randomized_controlled_trial_of_a_decision_aid_for_women_considering_genetic_testing_for_breast_and_ovarian_cancer_risk_ L2 - https://doi.org/10.1007/s10549-007-9539-2 DB - PRIME DP - Unbound Medicine ER -